title: Angiotensin-(1-7) inhibits vascular remodelling in rat jugular vein grafts via reduced ERK1/2 and p38 MAPK activity.
abstract: This study evaluated the effect of angiotensin (Ang)-(1-7) on vascular remodelling in a rat autologous jugular vein graft model in which rats underwent autologous jugular vein graft transplantation (Ang-[1-7] and control groups) or sham surgery (sham group). The animals  received continuous jugular infusion of Ang-(1-7) at 25 μg/kg per h (Ang-[1-7] group) or normal saline (control and sham groups) starting 3 days after surgery. Ang-(1-7) infusion reduced venous graft hyperplasia, vascular remodelling, extracellular signal-regulated kinase  1/2 (ERK1/2) activation, p38 mitogen-activated protein kinase (MAPK) activation and levels of proliferating cell nuclear antigen and α-smooth muscle actin compared with control animals. The vascular tissue Ang II level was higher in Ang-(1-7) and control rats than in sham animals.  These findings suggest that Ang-(1-7) acts by inhibiting the activation of ERK1/2 and p38 MAPK in vascular tissue. The use of exogenous Ang-(1-7) could improve the outcome of vein grafting through the attenuation of vascular remodelling.
authors.affiliation: Department of Cardiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
authors.forename: J-G
authors.initials: JG
authors.lastname: Wu
authors.forename: H
authors.initials: H
authors.lastname: Tang
authors.forename: Z-J
authors.initials: ZJ
authors.lastname: Liu
authors.forename: Z-F
authors.initials: ZF
authors.lastname: Ma
authors.forename: A-L
authors.initials: AL
authors.lastname: Tang
authors.forename: X-J
authors.initials: XJ
authors.lastname: Zhang
authors.forename: X-R
authors.initials: XR
authors.lastname: Gao
authors.forename: H
authors.initials: H
authors.lastname: Ma
mesh_terms: D000199:Actins / Q000378:metabolism; D000803:Angiotensin I / Q000008:administration & dosage / Q000494:pharmacology*; D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D001807:Blood Vessel Prosthesis; D001835:Body Weight / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D006439:Hemodynamics / Q000187:drug effects; D007262:Infusions, Intravenous; D007601:Jugular Veins / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology*; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014182:Transplantation, Autologous; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism*
chemical_list: D000199:Actins; D000803:Angiotensin I; D000804:Angiotensin II; D048049:Extracellular Signal-Regulated MAP Kinases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D010446:Peptide Fragments; D018809:Proliferating Cell Nuclear Antigen; D048051:p38 Mitogen-Activated Protein Kinases; C498862:Acta2 protein, rat; C118790:angiotensin I (1-7)